Scientists from Indee Labs apply TIMING to demonstrate reduced AICD and improved motility of hydroporated cells

TIMING applied to quantify motility, contact dynamics, spontaneous death, activation-induced cell death, and cytotoxicity of cells

PRESS RELEASE

Update: A manuscript was posted to bioRxiv in June 2024. The preprint can be viewed at this link.

HOUSTON, Texas — December 5, 2023 — CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how cells perform and interact over time, announced the publication by Indee Labs of a summary of how the CellChorus® TIMING™ platform was applied to compare Indee Labs’ hydroporation with conventional nucleofection for delivering genetic material into cells. The summary is titled “Microfluidic Vortex Shedding Enhances Genome-Edited Chimeric Antigen Receptor T Cell Function.”

The research team compared hydroporated cells with nucleofected cells. TIMING data showed that the methods were equally efficient in this experiment in causing CAR-T cells to seek and kill target cancer cells. Specifically, there were no significant differences in:

  • contact dynamics: percentage of synapse formation, time to synapse formation, and duration of synapse formation;

  • cytotoxicity: time to target cell death and percentage of target cell killed; and

  • spontaneous T cell death.

Notably, the team also evaluated CAR-T cell behavior before and after activation by a target cell. Data from the TIMING platform quantified that compared with nucleofected cells:

  • hydroporated cells exhibited significantly less activation-induced cell death (AICD); and

  • hydroporated cells exhibited improved motility as measured by the speed at which CAR-T cells migrated to subsequent target cells after being activated and forming synapses with target cancer cells.

“Cell therapies can lead to complete remission for certain cancer patients,” said Daniel Meyer, CEO of CellChorus. “We are excited by the multitude of advances in the industry to improve the safety and efficacy of these therapies and expand their use in new indications. Hydroporation shows exciting potential as a technology available in the field to improve the lives of patients.”

About CellChorus

CellChorus is the leader in applying artificial intelligence (AI) to visually evaluate how thousands of individual immune cells, such as T cells and NK cells, perform over time. The company applies Time lapse Imaging Microscopy in Nanowell Grids™ (TIMING™) with neural network-based AI to identify cells and evaluate their activity, including how they move, activate, kill and survive. The patent-protected CellChorus platform can link TIMING data and insights with information from other analysis modalities such as single-cell RNA sequencing and flow cytometry to provide a comprehensive understanding of cellular function, state and phenotype for the life sciences industry. Please visit cellchorus.com for more information.

Company Contact:
Daniel Meyer
Chief Executive Officer
CellChorus Inc.
TIMING@cellchorus.com

SOURCE CellChorus Inc.